The director of the MedStar Georgetown Headache Center discussed the upcoming International Congress on the Future of Neurology and what attendees can expect to hear from experts in migraine.
“[The migraine section of IFN] is a hybrid-type session, and I’m excited to see how that goes, because I have a feeling this is really the future of how conferences are going to be looking.”
The upcoming third annual International Congress on the Future of Neurology (IFN), held from September 17-18 at the InterContinental New York Barclay, will feature presentations on the most recent advancements in neurology, including migraine and headache. Jessica Ailani, MD, director, MedStar Georgetown Headache Center, spoke with NeurologyLive on the areas she is excited to see discussed.
Ailani, who will be running the section focused on migraine therapy, commented on the hybrid aspect of this year’s conference, with attendees able to visit in person or tune in virtually. Areas of interest for Ailani include the opening keynote lecture, given by Stephen Silberstein, MD, on new devices in migraine prevention and treatment. Silberstein, who the director of the headache center and professor of neurology at Jefferson Health, will speak specifically on neuromodulation, an area that has generated a large number of questions in both the patient and provider communities.
When asked about upcoming “hot topics” Ailani called attention to the novel calcitonin gene-related peptide treatments and how experts are making use of them. She further commented on treatment options to be discussed at IFN 2021 for patients with migraine, including acute treatment, preventive treatment, and nonpharmacological options such as behavioral therapies.